Get in Touch

PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens announced today that its Chief Executive Officer, Alexander Belcredi, will present at the Biotech Showcase 2020 Conference

Presenting at the Biotech Showcase, 2020 Tuesday, January 14, 2020 10:30 am PST
PhagoMed’s presentation at Biotech Showcase will cover its proprietary engineering platform, its lead assets and an outlook to the plans for 2020 and beyond.

VIENNA, Jan. 9, 2020 – PhagoMed Biopharma GmbH, (PhagoMed) a pre-clinical biotechnology company targeting bacterial pathogens in antibiotic resistance and microbiome settings, announced today that its chief executive officer, Alexander Belcredi, will present at the Biotech Showcase 2020 conference being held January 13-15, 2020 at the Hilton San Francisco Union Square in San Francisco, California.

Precisely targeting bacterial pathogens is the next big medical frontier. Today’s standard-of-care, small-molecule antibiotics, frequently fails due to resistance and is furthermore wholly inadequate in microbiome settings where broad-spectrum antibiotics not only destroy the pathogen but also destabilize the microbiome itself.

About PhagoMed

PhagoMed develops phage-based drug candidates to provide a solution in these settings where antibiotics fail. Phages are natural viruses that infect and kill bacteria. Phages and their proteins (such as lysins) are also highly precise and only target individual bacterial species. PhagoMed has developed a proprietary engineering platform to develop drug-grade phages and lysins. During 2019 the team validated the platform and generated two proprietary drug prototypes in two indications of high medical need: a phage cocktail to treat implant-associated infections and a recombinant endolysin to treat Bacterial Vaginosis and re-stabilize the vaginal microbiome.




Key Takeaways
  • Significant management experience in phage development. Team expanded in 2019 with accomplished research stars in new indications.
  • Strong traction in 2019: phage engineering platform validated, new patents, further compassionate treatment cases in Germany and follow-on investments ( >$7 million in total so far).
  • First phage candidate projected to enter the clinic in 2022.
Contacts
Alexander Belcredi
Alexander.belcredi@phagomed.com
+43-676 38 11 082
CEO | Business & Finance
Media Gallery
Video Gallery
Ted-Talk How a long-forgotten virus could help us solve the antibiotics crisis | Alexander Belcredi
View on Youtube
PhagoMed looks to raise $60M to scale up its bacterial infections treatment
View on Youtube
Related Bios
Alexander Belcredi, MBA
CEO | Business & Finance
View Full Bio>>
Dr. Lorenzo Corsini
CEO | Research & Development
View Full Bio>>
Dr. Christine Landlinger-Schuber
Director Lysins
View Full Bio>>
Files